目的：研究康萊特注射液在正常大鼠體內(nèi)的藥動學(xué)。方法：采用甘油三酯試劑盒檢測康萊特注射液經(jīng)尾iv后大鼠血清中外源性甘油三酯的濃度變化，外源性甘油三酯濃度為測定血樣中甘油三酯扣除本底后的濃度，采用3P97藥代軟件計算藥動學(xué)參數(shù)。C_max為實測值，AUC計算采用梯形法。結(jié)果：康萊特注射液10、5 mL/kg劑量的主要藥動學(xué)參數(shù)：C_max分別為（8.532±1.031）、（5.418±0.764）mmol/L，AUC_0-t分別為（13.248±3.692）、（5.339±1.219）mmol/L?h，V_c分別為（1.030±0.131）、（0.756±0.150）L²/（kg·mol），CL_s分別為（0.838±0.319）、（0.975±0.330）L²/（kg·mol·h），t _1/2α 分別為（0.481±0.168）、（0.322±0.109）h，t _1/2β分別為（1.452±0.776）、（1.384±0.404）h。結(jié)論：康萊特注射液經(jīng)尾iv給藥后在大鼠體內(nèi)的藥動學(xué)過程經(jīng)擬合為二室模型。

Objective: To study the in vivo pharmacokinetics of Kanglaite Injection in rats. Methods: The concentration change of exogenous triglyceride (TG) in rat serum was detected by TG Kit after iv administration of Kanglaite Injection in tail. The concentration of exogenous TG was the concentration after the background subtraction. Pharmacokinetic parameters were calculated by 3P97 software. C_max was the true value, AUC is obtained by the trapezoidal rule. Results: At the dosages of 10 and 5 mL/kg the main pharmacokinetic parameters of Kanglaite Injection were as follows: C_max=(8.532 ± 1.031) and (5.418 ± 0.764) mmol/L, AUC_0-t=(13.248 ± 3.692) and (5.339 ± 1.219) mmol/L?h, V_c=(1.030 ± 0.131) and (0.756± 0.150) L²/(kg·mol), CL_s=(0.838 ± 0.319) and (0.975 ± 0.330) L^{2/(kg·mol·h), t _{1/2 α}=(0.481 ± 0.168) and (0.322 ± 0.109) h, t _{1/2 β}=(1.452 ± 0.776) and (1.384 ± 0.404)h. Conclusion：The in vivo pharmacokinetic model of Kanglaite Injection after iv injection in rat tail is two compartment model.}

國家重點基礎(chǔ)研究計劃項目（973計劃）（2004BC581902）